comprehensive -WSS

comprehensive

author：fashion 2025-09-30 16:28:51 - browse：74225

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Bristol 'take

WSS

Bill would stop addiction treatment from triggering child abuse inquiry

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Ohioans vote in high

Former Georgia lieutenant governor says he received grand jury subpoena

Sage's campaign to raise awareness of postpartum depression hits a nerve

Analysis of telehealth claims data suggest service duplication

focus

comprehensive

hotspot

At least 13 dead in Texas as scorching temps continue

Liquid biopsy for lung cancer is launched by Delfi

Heart attack and stroke risk calculators need revising

3 questions for the future of Biden's cancer moonshot

Medical leaders decry Supreme Court decision on affirmative action

The painfully weak evidence on taking collagen to treat arthritis

As demand for Covid shots wanes, Moderna seeks its next success

AI can decode, harness the power of the humane immune system

In Memoriam: Notable people who died in 2023

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

focus

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Stroke deaths set to near 10 million globally by 2050

Why Charlie Gard's case is so disturbing to Americans

Phenylephrine and the overlooked value of the placebo effect

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

Ohioans vote in high

Wikipedia

Wikipedia

entertainment

knowledge